Scientists from Bonn University from Germany, along with their colleagues from Switzerland, have shown that by combining two drugs the treatment of glioblastoma, the brain tumor, becomes extremely successful.
Glioblastoma is a deadly type of brain cancer, which caused death within a couple of weeks if it’s not treated. The researchers from Germany and Switzerland performed the research on 40 patients with their new therapy, and ended up with amazing results. The patients survived over 2 years. They then compared those results with the ones when regular treatment was used, and came to a conclusion that this therapy doubled the survival time (from 1 to 2 years, on average).
“This unusually manifest extension of the survival time has surprised even us. Our results offer the opportunity to improve our grip on this aggressive form of cancer. Now, further investigations involving a larger number of patients are needed to optimise this therapy. Planning for this is already in hand in Bonn,” said Dr. Ulrich Herrlinger, one of the researchers.
Glioblastoma was treated with both radio- and chemotherapy (agent temozolomide). What scientists did in this research is add lomustine to chemotherapy, and continued to use radiotherapy.
The details are published in the Journal of Clinical Oncology.
Adopted from materials provided by uni-bonn.de